SHH · 600276.SS
Jiangsu Hengrui Medicine Co., Ltd.
CN¥49.03+CN¥0.41 (+0.84%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.52% below the high.
Loading market information…
SHH · 688180.SS · CNY
Stock price, earnings
Quote as of Oct 30, 2026, 03:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Shanghai Junshi Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Shanghai Junshi Biosciences Co., Ltd.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shanghai Junshi Biosciences Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥49.03+CN¥0.41 (+0.84%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.52% below the high.
CN¥255.62+CN¥1.93 (+0.76%)
BeOne Medicines Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 19.93% below the high.
CN¥95.50+CN¥1.88 (+2.01%)
RemeGen Co. Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 39.48% below the high.
CN¥83.15+CN¥0.12 (+0.14%)
Shanghai Allist Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.88% below the high.
CN¥32.44+CN¥0.33 (+1.03%)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 51.31% below the high.
CN¥85.00+CN¥0.80 (+0.95%)
Suzhou Zelgen Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
CN¥17.18+CN¥0.20 (+1.18%)
Staidson (Beijing) BioPharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.27% below the high.
CN¥21.47+CN¥0.12 (+0.56%)
Mabwell (Shanghai) Bioscience Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 55.71% below the high.
